Key Points
- CEO Eric Venker sold 200,000 Roivant Sciences shares at an average price of $36.59, generating $7.32 million. The Rule 10b5-1 transaction reduced his stake by 14.29% to approximately 1.2 million shares.
- Venker has conducted three additional 200,000-share sales since late August, indicating a pattern of insider selling totaling roughly $28.8 million across the four transactions.
- Roivant shares opened at $36.91, while analysts maintain a consensus “Moderate Buy” rating with an average price target of $46.55; the company recently beat quarterly EPS estimates but missed revenue expectations.
Roivant Sciences Ltd. (NASDAQ:ROIV - Get Free Report) CEO Eric Venker sold 200,000 shares of the firm's stock in a transaction on Wednesday, October 28th. The shares were sold at an average price of $36.59, for a total value of $7,318,000.00. Following the completion of the transaction, the chief executive officer owned 1,199,154 shares of the company's stock, valued at approximately $43,877,044.86. This represents a 14.29% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Eric Venker also recently made the following trade(s):
- On Tuesday, October 20th, Eric Venker sold 200,000 shares of Roivant Sciences stock. The stock was sold at an average price of $35.11, for a total value of $7,022,000.00.
- On Wednesday, September 30th, Eric Venker sold 200,000 shares of Roivant Sciences stock. The stock was sold at an average price of $36.62, for a total transaction of $7,324,000.00.
- On Friday, August 28th, Eric Venker sold 200,000 shares of Roivant Sciences stock. The shares were sold at an average price of $35.77, for a total transaction of $7,154,000.00.
Roivant Sciences Stock Performance
Shares of ROIV opened at $36.91 on Friday. The company has a 50-day moving average of $36.65 and a two-hundred day moving average of $31.46. Roivant Sciences Ltd. has a 12-month low of $19.30 and a 12-month high of $42.50.
Roivant Sciences (NASDAQ:ROIV - Get Free Report) last released its quarterly earnings results on Friday, August 7th. The company reported ($0.26) EPS for the quarter, beating the consensus estimate of ($0.30) by $0.04. The business had revenue of $1.44 million for the quarter, compared to analyst estimates of $2.06 million. Roivant Sciences had a negative net margin of 3,534.96% and a negative return on equity of 22.94%. On average, equities research analysts expect that Roivant Sciences Ltd. will post -2.00 earnings per share for the current year.
Institutional Trading of Roivant Sciences
Several hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Alpine Bank Wealth Management purchased a new position in shares of Roivant Sciences during the 3rd quarter worth about $25,000. Compass Financial Management LLC acquired a new stake in shares of Roivant Sciences in the third quarter worth approximately $37,000. Parallel Advisors LLC boosted its position in shares of Roivant Sciences by 33.7% in the first quarter. Parallel Advisors LLC now owns 2,065 shares of the company's stock worth $57,000 after acquiring an additional 520 shares during the last quarter. Bessemer Group Inc. grew its holdings in Roivant Sciences by 21.8% in the first quarter. Bessemer Group Inc. now owns 2,465 shares of the company's stock valued at $69,000 after purchasing an additional 441 shares during the period. Finally, Root Financial Partners LLC grew its holdings in Roivant Sciences by 187.9% in the first quarter. Root Financial Partners LLC now owns 2,914 shares of the company's stock valued at $81,000 after purchasing an additional 1,902 shares during the period. Hedge funds and other institutional investors own 64.76% of the company's stock.
Wall Street Analysts Forecast Growth
A number of equities research analysts recently issued reports on the company. TD Cowen reaffirmed a "buy" rating on shares of Roivant Sciences in a research note on Wednesday, October 21st. UBS Group set a $55.00 price target on Roivant Sciences in a research report on Wednesday, September 9th. Cantor Fitzgerald reissued an "overweight" rating on shares of Roivant Sciences in a report on Thursday, September 24th. Guggenheim upped their price objective on Roivant Sciences from $42.00 to $46.00 and gave the company a "buy" rating in a research report on Wednesday, September 9th. Finally, Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Roivant Sciences in a research note on Wednesday, August 19th. One equities research analyst has rated the stock with a Strong Buy rating, ten have issued a Buy rating, two have given a Hold rating and one has given a Sell rating to the company's stock. According to data from MarketBeat.com, Roivant Sciences has a consensus rating of "Moderate Buy" and an average target price of $46.55.
Read Our Latest Research Report on Roivant Sciences
Roivant Sciences Company Profile
(
Get Free Report)
Roivant Sciences Ltd. (NASDAQ: ROIV) is a biopharmaceutical company focused on discovering, developing and commercializing medicines. The company organizes its activities through subsidiaries and partner companies, often referred to as “Vants,” which specialize in particular therapeutic areas and stages of drug development.
Roivant's research and development activities have included immunology, dermatology, women's health, rare diseases and other specialty-care fields. Its portfolio has included Vtama (tapinarof) cream, a nonsteroidal topical treatment approved in the United States for plaque psoriasis and atopic dermatitis.
Recommended Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
